Quintet Private Bank Europe S.A. Reduces Position in Thermo Fisher Scientific Inc. $TMO

Quintet Private Bank Europe S.A. decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,973 shares of the medical research company’s stock after selling 5,580 shares during the period. Thermo Fisher Scientific makes up about 1.8% of Quintet Private Bank Europe S.A.’s portfolio, making the stock its 14th biggest holding. Quintet Private Bank Europe S.A.’s holdings in Thermo Fisher Scientific were worth $32,483,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of TMO. Brighton Jones LLC raised its position in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Watts Gwilliam & Co. LLC acquired a new position in Thermo Fisher Scientific during the first quarter valued at $218,000. Wellington Management Group LLP boosted its holdings in Thermo Fisher Scientific by 11.7% in the first quarter. Wellington Management Group LLP now owns 1,595,715 shares of the medical research company’s stock valued at $794,028,000 after purchasing an additional 167,763 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc grew its position in Thermo Fisher Scientific by 181.6% during the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 2,267 shares of the medical research company’s stock worth $1,128,000 after purchasing an additional 1,462 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TMO. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Morgan Stanley upped their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Cowen reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Argus increased their price target on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $616.60.

Thermo Fisher Scientific Trading Down 1.0%

Shares of NYSE:TMO opened at $570.07 on Wednesday. The firm has a market capitalization of $214.18 billion, a price-to-earnings ratio of 32.93, a price-to-earnings-growth ratio of 4.21 and a beta of 0.90. The business’s 50 day moving average price is $567.10 and its 200-day moving average price is $494.60. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock repurchase plan on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 10,225 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the sale, the vice president directly owned 14,145 shares of the company’s stock, valued at $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Frederick M. Lowery sold 6,913 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $597.68, for a total value of $4,131,761.84. Following the completion of the transaction, the executive vice president directly owned 14,367 shares of the company’s stock, valued at approximately $8,586,868.56. This represents a 32.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 149,271 shares of company stock valued at $86,507,282. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.